AbSci Raises Oversubscribed $12M Series C to Fuel Commercialization of Its Groundbreaking Protein Expression Platform
The Series C Round led by Asahi Glass Co., Ltd. “AGC” includes participation from all prior investors (Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Souther Co.) and new investors Columbia Ventures Corporation and GreenBridge.
AbSci, a global leader in breakthrough biomanufacturing technologies, announced that it closed its Series B financing round for an undisclosed amount. The round includes previous investors along with several new investors …
“I wasn’t there when Bill Boeing did his seaplane or when Bill Gates was coming up with software programs. But I’m here,” Inslee told Sean McClain, founder and CEO of AbSci, on Monday.